Alzheimer's disease can affect the olfactory bulb and parts of the brain, resulting in difficulty with the sense of smell. Researchers will determine if this difficulty can predict the conversion to Alzheimer's disease in people with amnestic mild cognitive impairment (MCI) and track participants' response to therapy with the Alzheimer's drug donepezil.
|Min Age||Max Age||Gender||Healthy Volunteers|
During this 1-year study, investigators will evaluate, treat, and follow 60 older adults with amnestic MCI, who will receive memory and olfactory assessments at weeks 8, 26, and 52. Atropine nasal spray will be administered for participants to take an odor detection and identification test, after which treatment with the Alzheimer's drug donepezil will start and continue for 52 weeks. Participants who cannot tolerate donepezil can take galantamine or rivastigmine, which are similar drugs. This project will help select people with MCI for treatment based on the ability of olfaction tests to predict response to donepezil and similar drugs.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 40.8409822, -73.9447994
New York State Psychiatric Institute
Department of Defense
Davangere Devanand, MD
Gregory Pelton, MD